Interclean Shanghai

CloudCath raises funds towards peritoneal dialysis monitoring system

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

EU Begins Revision of Medical Device...

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical...

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Digital health medical device company CloudCath has completed a $12m Series A funding round to commercialise a system that enables remote and live monitoring for patients undergoing at-home peritoneal dialysis.

It also plans to use the funds to support the development of additional applications utilising the company’s proprietary technology. Capital Integral led the funding round, with participation from FundRx, The Capital Partnership, Coconut Tree Investments, Stanford University’s StartX Fund and additional strategic and individual investors.

Seamlessly integrating into the patient’s drain line, CloudCath’s device helps to monitor the spent dialysate fluid on every dialysis cycle by measuring and quantifying the fluid properties remotely from the patients’ home.

CloudCath’s monitoring platform helps healthcare providers to log in and access real-time data from patients throughout treatment, to assist in decision management. CloudCath co-founder and CEO Aly ElBadr said: “End-stage renal disease, one of the costliest chronic diseases in the US, is devastating to patients.

“The CloudCath technology enables patients and caregivers to easily monitor fluid parameters for early signs of complications, including infection, in real-time, allowing dialysis providers to intervene much earlier than the existing standard of care.

Latest stories

Related stories

EU Begins Revision of Medical Device Regulatory Framework

The European Commission has gone on to initiate a...

FDA Seeks Opinion on AI-Enabled Medical Devices Regulation

The U.S. Food and Drug Administration (US FDA) is...

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »